Date Time Share Dana-Farber, Broad Institute and Count Me In receive $16 million grant to launch patient-partnered research initiatives Funding from the National Cancer Institute will help optimize patient engagement in research while studying osteosarcoma and leiomyosarcoma Dana-Farber Cancer Institute, The Broad Institute of MIT and Harvard, and Count Me In, a non-profit research initiative that conducts patient-partnered studies of cancer, have been awarded a new $16 million grant from the National Cancer Institute, to accelerate research in two rare forms of cancer. The funding will support research projects in leiomyosarcoma and osteosarcoma, two cancers which have seen few recent therapeutic advances, while simultaneously yielding new information about the best ways to engage with patients traditionally underrepresented in cancer research. The goal of these projects is to accelerate discoveries that can drive new insights into the genomic roots of rare cancer, discover mechanisms of resistance to therapies, and uncover potential new treatment strategies.